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Chloride and the measurement of
acid transport
To the Editor: Xu et al.1 in a recent paper described the
involvement of Slc26a11 in renal acid excretion. Assessing
cellular systems, the interpretation is that Slc26a11 ‘is a partner of
vacuolar Hþ -ATPase facilitating acid secretion in the collecting
duct’. This was based on comparing the change in pH over time
after acidiﬁcation using a prepulse of ammonium. Buffering
power was measured by the ammonium method, and thus a
ﬂux of Hþ should, in principle, be available, which may be
preferable.2 Not referenced by Xu et al.1 or by the accompanying
comment, Stone et al.3 in 1983 assessed the anion dependence of
rabbit medullary collecting duct acidiﬁcation by tubular perfu-
sion. Removing chloride from the bath completely abolished
tubular acidiﬁcation, and the ﬂux of Cl in pmolmin1mm1
was very similar to that of HCO3
 over a range of values. Stone
et al.3 suggested the presence of an apical Cl conductance under
acidosis, whereas Palmer and Frindt4 failed to detect an apical Cl
conductance at all in the rat using whole-cell clamping but
without initial intracellular acidiﬁcation. In addition, Hamm
et al.5 believe that functional Cl channels are not found in the
apical membrane of acid-secreting intercalated cells.5 Now Xu
et al.1 report the Cl transport by Slc26a11 as an enhancement of
H-ATPase-mediated intracellular alkalinization after initial
acidiﬁcation. It would be of great interest to know whether this
effect and the accompanying Cl transport were dependent on
initial pH. Reconciliation of the newer results from molecular
biology with older (more) direct measurements,3 qualitatively
and quantitatively, is very important.
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The Author Replies: I read with great interest the comments
by Dr Ring1 regarding our recent studies about the role of
Slc26a11 (kidney brain anion transporter, KBAT) in Hþ -
ATPase.2 Our studies demonstrated that Slc26a11 (KBAT)
colocalizes with Hþ -ATPase on the apical membrane of the
kidney A-intercalated cells, and activates Hþ -ATPase-mediated
acid secretion in cultured cells in a chloride-dependent
manner.2 On the basis of previously published data, Dr Ring
indicates that the presence of an apical chloride conductance
in intercalated cells and its role in acid secretion have been the
subject of conﬂicting reports, with one article supporting its
role in acid secretion and another article not.3,4 The studies by
Stone et al.3 speciﬁcally tested the role of apical chloride
conductance under intracellular acidosis. Dr Ring is inquiring
whether the activation of Hþ -ATPase and the accompanying
Cl transport by KBAT were dependent on the initial pH.
In our studies, the stimulatory role of KBAT in Hþ -ATPase-
mediated acid secretion was observed in acid-loaded cells,2
resembling the experimental conditions utilized by Stone et al.3
We would like to indicate that in cultured cells, Hþ -ATPase
activity is best observed under intracellular acidosis, and cells at
baseline condition do not show robust Hþ -ATPase activity.
Our recent patch clamp studies in cultured cells demon-
strate that KBAT indeed functions as a chloride channel
(Kunzelmann and Soleimani, personal observation). Coupled
with the immunolocalization studies,2 we strongly believe that
KBAT is the ﬁrst apical chloride channel molecule identiﬁed in
A-intercalated cells. We suggest that the deﬁnitive answer to Dr
Ring’s inquiry will come from the studies on Slc26a11 (KBAT)
conditional knockout mice already in ﬁnal stages of generation
in our laboratories.
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Serum-soluble urokinase receptor
concentration in primary FSGS
To the Editor: Recently Wei et al.1 suggested that
measurement of serum-soluble urokinase receptor (suPAR)
is valuable in patients with idiopathic nephrotic syndrome.
Serum suPAR concentration was elevated in patients with
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focal segmental glomerulosclerosis (FSGS) and not in patients
with other glomerular diseases. The authors proposed that
high serum suPAR (X3000 pg/ml) is speciﬁc for primary
FSGS. However, in many of their patients with suspected
primary FSGS, serum albumin was normal or unknown. The
absence of hypoalbuminemia despite heavy proteinuria
suggests that FSGS is due to hyperﬁltration rather than
primary FSGS.2 It is also unknown whether suPAR is
associated with response to corticosteroids. To determine
the value of suPAR in routine clinical practice we measured
suPAR concentration in sera of adult patients with idiopathic
(primary) FSGS (n¼ 11), secondary FSGS (hyperﬁltration
n¼ 3, familial n¼ 2), and minimal change disease (MCD; n¼ 7)
with the Quantikine Human suPAR Immunoassay (R&D
Systems, Minneapolis, MN). Median serum suPAR concentra-
tion was not different between idiopathic FSGS (2392 pg/ml),
secondary FSGS (2716 pg/ml), and MCD (2482 pg/ml),
nor did it predict steroid responsiveness in patients with
idiopathic FSGS/MCD (Figure 1). We found a negative cor-
relation between suPAR and estimated glomerular ﬁltration
rate Modiﬁcation of Diet in Renal Disease (MDRD)-6
(Figure 2). In conclusion, suPAR concentration is not a
speciﬁc marker for idiopathic FSGS in this study and it does
not reliably predict response to treatment. Although our data
indicate that for the individual patient suPAR is not a reliable
marker, the small size of our study does not allow deﬁnite
conclusions on the role of suPAR in FSGS. A larger study is
needed to clarify this issue.
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The contribution of chronic kidney
disease to the global burden of
major noncommunicable diseases
To the Editor: We have read the report of the ISN Global
Outreach Programme,1 which conﬁrms that, for the less
developed countries compared with the more developed ones,
chronic glomerulonephritis (GN) and not diabetic nephrop-
athy (DiabNx) is still the leading cause of end-stage renal
failure (ESRF).
The more developed Asian countries including Singapore,
Malaysia, India, and China are now faced with the burden
of diseases associated with lifestyle changes, such as diabetes
mellitus and obesity. Despite the decreasing prevalence of
chronic kidney disease-associated proteinuria due to chronic
GN and hypertensive nephrosclerosis, as a result of programs
to control and retard progression in these two diseases, the
dilemma of the epidemic proportion of DiabNx is far from
being contained. In Singapore, the incidence of DiabNx as a
cause of ESRF in 1983 was 17%, in 2004 it was 58%, and in
2008 it further rose to 63% in patients initiating dialysis.2
However, the incidence of ESRF has stabilized over the past
3 years. In 1975, it was 90 per million population (p.m.p.),
with a progressive increase to peak at 264 p.m.p. in 2007. Over
the past 3 years (2006–2008), it has remained at 238, 264, and
245 p.m.p. (ever start dialysis) or 207, 212, and 211 p.m.p.
(survive 90 days of dialysis).2
Angiotensin-converting enzyme inhibitors/angiotensin
receptor blockers (ACEIs/ARBs) have been around for years,
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Figure 1 | Serum suPAR concentrations in patients with
idiopathic focal segmental glomerulosclerosis (FSGS),
minimal change disease (MCD) and secondary FSGS. Median
suPAR concentration is indicated by the horizontal line.
n, steroid-sensitive (complete remission); m, steroid-resistant
(no remission); , no immunosuppressive therapy.
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Figure 2 |Correlation analysis of suPAR with estimated
glomerular filtration rate (eGFR) MDRD-6. Spearman’s rho
0.46, P¼ 0.03.
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